Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

When ethics collides with a legal gap in emergency life-threatening conditions.

British journal of anaesthesia·2018

Same author

Uric acid levels are independent of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease: A reappraisal of the role of S. cerevisiae in this setting.

Virulence·2018

Same author

The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease.

United European gastroenterology journal·2018

Same author

Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents.

The American journal of gastroenterology·2017

Same author

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.

Alimentary pharmacology & therapeutics·2017

Same author

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Alimentary pharmacology & therapeutics·2017

Search research articles

Related Experiment Videos

Inflammation affects sufentanil consumption in ulcerative colitis.

M Fleyfel¹, C Dusson, M-L Ousmane

¹CHRU de Lille, Federation of Anesthesiology and Intensive Care Medecine, Lille Cedex, France. m-fleyfel@chrulille.fr

European Journal of Anaesthesiology

|September 26, 2007

Summary

This summary is machine-generated.

Inflammation significantly increases opioid needs in ulcerative colitis surgery. Patients required double the sufentanil during acute inflammation compared to recovery periods, highlighting the impact of inflammatory status on anesthesia management.

Related Experiment Videos

Area of Science:

Anesthesiology
Gastroenterology
Surgical Oncology

Background:

Previous research indicates elevated perioperative opioid requirements in inflammatory conditions.
Ulcerative colitis (UC) presents distinct inflammatory profiles during acute phases versus remission.

Purpose of the Study:

To assess the influence of UC's inflammatory status on intraoperative sufentanil requirements within the same patient.
To compare opioid needs during colectomy for acute inflammation versus coloprotectomy after remission.

Main Methods:

Sixteen UC patients underwent two procedures: colectomy during acute inflammation and coloprotectomy after remission.
Anesthesia involved sufentanil, propofol, and isoflurane, with continuous sufentanil infusion for analgesia.
Opioid consumption was analyzed using the Wilcoxon signed rank sum test, with P < 0.05 considered significant.

Main Results:

Total intraoperative sufentanil requirement was significantly higher during colectomy for acute inflammatory colitis (1.24 ± 0.48 μg kg⁻¹ h⁻¹) compared to coloprotectomy after remission (0.62 ± 0.3 μg kg⁻¹ h⁻¹).
The difference in sufentanil consumption between the two phases was statistically significant (P < 0.05).

Conclusions:

A patient's inflammatory status directly impacts opioid requirements during surgery for ulcerative colitis.
Anesthesia management for UC patients should consider the degree of intestinal inflammation.